Weekly Digest – January 2026 Weekly Digest – January 2026 27 January 2026: Henlius receives an IND approval for Its PD-L1-targeting ADC HLX43 in combination with anti-PD-1 mAb Serplulimab and novel anti-EGFR mAb HLX07 Shanghai Henlius Biotech has secured regulatory […]
Weekly Digest – January 2026 Weekly Digest – January 2026 29 January 2026: MT-2111 (loncastuximab tesirine-lpyl) achieved primary endpoint in phase 2 part of Japanese phase 1/2 study for relapsed or refractory Diffuse Large B-cell Lymphoma Tanabe Pharma announced a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: China Isotope & Radiation Corporation signs commercial deal for Pluvicto, China’s first PSMA radioligand therapy China Isotope & Radiation Corporation disclosed that its subsidiary, Atom High-Tech, has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 January 2026: HealZen announces global strategic collaboration to Develop degrader-antibody conjugate therapeutics HealZen Therapeutics has taken a major step onto the global stage, announcing a strategic collaboration with a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 January 2026: Fortitude Biomedicines launches with $13M in financing to advance novel antibody-based therapies for treatment of autoimmune diseases and cancer Fortitude Biomedicines has officially launched with $13 million […]
Weekly Digest – January 2026 Weekly Digest – January 2026 27 January 2026: StarkAge Therapeutics announces research collaboration with Gustave Roussy to advance senolytic therapies in digestive cancers StarkAge Therapeutics has entered a strategic research collaboration with Gustave Roussy, Europe’s […]
